The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of lapatinib in combination with vinorelbine in patients with ErbB2-amplified recurrent or metastatic breast cancer.
P. Saip
No relevant relationships to disclose
Y. Eralp
No relevant relationships to disclose
M. Ozkan
No relevant relationships to disclose
H. Karaca
No relevant relationships to disclose
M. Benekli
No relevant relationships to disclose
B. Cetin
No relevant relationships to disclose
A. Isikdogan
No relevant relationships to disclose
M. Kucukoner
No relevant relationships to disclose
G. Basaran
No relevant relationships to disclose
F. Sen
No relevant relationships to disclose
O. Un
No relevant relationships to disclose
H. Onur
No relevant relationships to disclose